Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 10/2004

01-10-2004 | Original Paper

Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells

Authors: Ryuji Yasumatsu, Torahiko Nakashima, Muneyuki Masuda, Aya Ito, Yuichiro Kuratomi, Takashi Nakagawa, Shizuo Komune

Published in: Journal of Cancer Research and Clinical Oncology | Issue 10/2004

Login to get access

Abstract

Purpose

Recently, it has been reported that angiotensin-I converting enzyme (ACE) inhibitors have anticancer activity. In particular, the ACE inhibitor, perindopril, significantly inhibits tumor growth and angiogenesis in hepatocellular carcinoma cells along with suppression of the VEGF level. However, the mechanisms of suppression of the VEGF level are still unclear, and there are no previous reports on this subject related to head and neck squamous cell carcinoma (HNSCC). In some previous studies, angiotensin II, which is produced from angiotensin I by ACE, directly stimulates VEGF expression.

Methods

In the present study, we focused upon angiotensin II, and investigated the effect of perindopril on VEGF expression, angiogenesis, and tumor development of HNSCC with in vitro and in vivo studies.

Results

In the in vitro cell proliferation assays, there was no significant difference between the perindopril-treated group and the control group. However, the perindoprilat-treated group showed a significant reduction in mRNA expression of VEGF and inhibited the induction activity of the VEGF promoter in comparison to the control group. Perindoprilat treatment also significantly suppressed angiotensin II production in vitro. In the in vivo studies, perindopril had a significant inhibitory effect on tumor growth, and reduced blood vessel formation surrounding the tumors.

Conclusions

Our findings suggest that perindopril has no direct cytotoxicity against tumor cells, but has a potential to inhibit tumor growth due to suppression of VEGF-induced angiogenesis in vivo. Angiotensin II might have an important role in carcinogenesis, and the antiangiogenic activity of perindopril is at least partly mediated by angiotensin II inhibition. The ACE inhibitor perindopril has clinical potential as a useful antitumor agent.
Literature
go back to reference Bosari S, Lee AK, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML (1992) Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 23:755–761CrossRefPubMed Bosari S, Lee AK, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML (1992) Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 23:755–761CrossRefPubMed
go back to reference Burris JF (1995) The expanding role of angiotensin converting enzyme inhibitors in the management of hypertension. J Clin Pharmacol 35:337–342PubMed Burris JF (1995) The expanding role of angiotensin converting enzyme inhibitors in the management of hypertension. J Clin Pharmacol 35:337–342PubMed
go back to reference Chen L, Re RN, Prakash O, Mondal D (1991) Angiotensin-converting enzyme inhibition reduces neuroblastoma cell growth rate. Proc Soc Exp Biol Med 196:280–283PubMed Chen L, Re RN, Prakash O, Mondal D (1991) Angiotensin-converting enzyme inhibition reduces neuroblastoma cell growth rate. Proc Soc Exp Biol Med 196:280–283PubMed
go back to reference Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM (1991) Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 68:450–456PubMed Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM (1991) Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 68:450–456PubMed
go back to reference Denhart BC, Guidi AJ, Tognazzi K, Dvorak HF, Brown LF (1997) Vascular permeability factor/vascular endothelial growth factor and its receptors in oral and laryngeal squamous cell carcinoma and dysplasia. Lab Invest 77:659–664PubMed Denhart BC, Guidi AJ, Tognazzi K, Dvorak HF, Brown LF (1997) Vascular permeability factor/vascular endothelial growth factor and its receptors in oral and laryngeal squamous cell carcinoma and dysplasia. Lab Invest 77:659–664PubMed
go back to reference Fernandez LA, Twickler J, Mead A (1985) Neovascularization produced by angiotensin II. J Lab Clin Med 105:141–145PubMed Fernandez LA, Twickler J, Mead A (1985) Neovascularization produced by angiotensin II. J Lab Clin Med 105:141–145PubMed
go back to reference Ferrara N, Alitalo K (1999) Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5:1359–1364CrossRefPubMed Ferrara N, Alitalo K (1999) Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5:1359–1364CrossRefPubMed
go back to reference Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4–6CrossRefPubMed Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4–6CrossRefPubMed
go back to reference Folkman J, Shing Y (1992) Angiogenesis. J Biol Chem 267:10931–10934PubMed Folkman J, Shing Y (1992) Angiogenesis. J Biol Chem 267:10931–10934PubMed
go back to reference Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M (2002) Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 294:441–447CrossRefPubMed Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M (2002) Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 294:441–447CrossRefPubMed
go back to reference Garg R, Yusuf S (1995) Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 273:1450–1456CrossRefPubMed Garg R, Yusuf S (1995) Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 273:1450–1456CrossRefPubMed
go back to reference Kimura H, Weisz A, Kurashima Y, Hashimoto K, Ogura T, D’Acquisto F, Addeo R, Makuuchi M, Esumi H (2000) Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 95:189–197PubMed Kimura H, Weisz A, Kurashima Y, Hashimoto K, Ogura T, D’Acquisto F, Addeo R, Makuuchi M, Esumi H (2000) Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 95:189–197PubMed
go back to reference Kuiper RA, Schellens JH, Blijham GH, Beijnen JH, Voest EE (1998) Clinical research on antiangiogenic therapy. Pharmacol Res 37:1–16CrossRefPubMed Kuiper RA, Schellens JH, Blijham GH, Beijnen JH, Voest EE (1998) Clinical research on antiangiogenic therapy. Pharmacol Res 37:1–16CrossRefPubMed
go back to reference Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, Robertson JW (1998) Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352:179–184CrossRefPubMed Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, Robertson JW (1998) Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352:179–184CrossRefPubMed
go back to reference Masuda M, Toh S, Koike K, Kuratomi Y, Suzui M, Deguchi A, Komiyama S, Weinstein IB (2002). The roles of JNK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil. Jpn J Cancer Res 93:329–339PubMed Masuda M, Toh S, Koike K, Kuratomi Y, Suzui M, Deguchi A, Komiyama S, Weinstein IB (2002). The roles of JNK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil. Jpn J Cancer Res 93:329–339PubMed
go back to reference Matsumoto G, Ohmi Y, Shindo J (2001) Angiostatin gene therapy inhibits the growth of murine squamous cell carcinoma in vivo. Oral Oncol 37:369–378CrossRefPubMed Matsumoto G, Ohmi Y, Shindo J (2001) Angiostatin gene therapy inhibits the growth of murine squamous cell carcinoma in vivo. Oral Oncol 37:369–378CrossRefPubMed
go back to reference Minchenko A, Salceda S, Bauer T, Caro J (1994) Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cell Mol Biol Res 40:35–39PubMed Minchenko A, Salceda S, Bauer T, Caro J (1994) Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cell Mol Biol Res 40:35–39PubMed
go back to reference Moriyama M, Kumagai S, Kawashiri S, Kojima K, Kakihara K, Yamamoto E (1997) Immunohistochemical study of tumour angiogenesis in oral squamous cell carcinoma. Oral Oncol 33:369–374PubMed Moriyama M, Kumagai S, Kawashiri S, Kojima K, Kakihara K, Yamamoto E (1997) Immunohistochemical study of tumour angiogenesis in oral squamous cell carcinoma. Oral Oncol 33:369–374PubMed
go back to reference Mustonen T, Alitalo K (1995) Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 129:895–898CrossRefPubMed Mustonen T, Alitalo K (1995) Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 129:895–898CrossRefPubMed
go back to reference Noguchi R,Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Mitoro A, Tsujinoue H, Imazu H, Masaki T, Fukui H (2003) Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin Cancer Res 9:6038–6045PubMed Noguchi R,Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Mitoro A, Tsujinoue H, Imazu H, Masaki T, Fukui H (2003) Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin Cancer Res 9:6038–6045PubMed
go back to reference Page EL, Robitaille GA, Pouyssegur J, Richard DE (2002) Induction of hypoxia-inducible factor-1alpha by transcriptional and translational mechanisms. J Biol Chem 277:48403–48409CrossRefPubMed Page EL, Robitaille GA, Pouyssegur J, Richard DE (2002) Induction of hypoxia-inducible factor-1alpha by transcriptional and translational mechanisms. J Biol Chem 277:48403–48409CrossRefPubMed
go back to reference Prontera C, Mariani B, Rossi C, Poggi A, Rotilio D (1999) Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer 81:761–766CrossRefPubMed Prontera C, Mariani B, Rossi C, Poggi A, Rotilio D (1999) Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer 81:761–766CrossRefPubMed
go back to reference Shemirani B, Crowe DL (2000) Head and neck squamous cell carcinoma lines produce biologically active angiogenic factors. Oral Oncol 36:61–66CrossRefPubMed Shemirani B, Crowe DL (2000) Head and neck squamous cell carcinoma lines produce biologically active angiogenic factors. Oral Oncol 36:61–66CrossRefPubMed
go back to reference Shemirani B, Crowe DL (2002) Hypoxic induction of HIF-1alpha and VEGF expression in head and neck squamous cell carcinoma lines is mediated by stress activated protein kinases. Oral Oncol 38:251–257CrossRefPubMed Shemirani B, Crowe DL (2002) Hypoxic induction of HIF-1alpha and VEGF expression in head and neck squamous cell carcinoma lines is mediated by stress activated protein kinases. Oral Oncol 38:251–257CrossRefPubMed
go back to reference Shpitzer T, Chaimoff M, Gal R, Stern Y, Feinmesser R, Segal K (1996) Tumor angiogenesis as a prognostic factor in early oral tongue cancer. Arch Otolaryngol Head Neck Surg 122:865–868PubMed Shpitzer T, Chaimoff M, Gal R, Stern Y, Feinmesser R, Segal K (1996) Tumor angiogenesis as a prognostic factor in early oral tongue cancer. Arch Otolaryngol Head Neck Surg 122:865–868PubMed
go back to reference Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, Molteni A, Polverini PJ, Bouck NP (1996) Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98:671–679PubMed Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, Molteni A, Polverini PJ, Bouck NP (1996) Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98:671–679PubMed
go back to reference Yoshiji H, Kuriyama S, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Fukui H (2001) The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 7:1073–1078PubMed Yoshiji H, Kuriyama S, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Fukui H (2001) The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 7:1073–1078PubMed
go back to reference Yoshiji H, Kuriyama S, Fukui H (2002) Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol 23:348–356CrossRefPubMed Yoshiji H, Kuriyama S, Fukui H (2002) Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol 23:348–356CrossRefPubMed
Metadata
Title
Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells
Authors
Ryuji Yasumatsu
Torahiko Nakashima
Muneyuki Masuda
Aya Ito
Yuichiro Kuratomi
Takashi Nakagawa
Shizuo Komune
Publication date
01-10-2004
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 10/2004
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-004-0582-7

Other articles of this Issue 10/2004

Journal of Cancer Research and Clinical Oncology 10/2004 Go to the issue